PureTech Health plc

DB:0VQ Stock Report

Market Cap: €493.2m

PureTech Health Valuation

Is 0VQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0VQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0VQ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0VQ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0VQ?

Key metric: As 0VQ barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0VQ. This is calculated by dividing 0VQ's market cap by their current book value.
What is 0VQ's PB Ratio?
PB Ratio1.6x
BookUS$315.87m
Market CapUS$513.61m

Price to Book Ratio vs Peers

How does 0VQ's PB Ratio compare to its peers?

The above table shows the PB ratio for 0VQ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
FYB Formycon
1.4x31.5%€827.2m
BIO3 Biotest
2x29.3%€1.4b
HPHA Heidelberg Pharma
2.9x-33.0%€103.9m
MDG1 Medigene
1.2x-4.1%€22.6m
0VQ PureTech Health
1.6x-13.0%€409.9m

Price-To-Book vs Peers: 0VQ is good value based on its Price-To-Book Ratio (1.6x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does 0VQ's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
0VQ 1.6xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0VQ is good value based on its Price-To-Book Ratio (1.6x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is 0VQ's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0VQ PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0VQ's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0VQ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.93
€6.72
+248.0%
18.6%€7.97€5.47n/a2
Nov ’25€1.79
€6.72
+275.2%
18.6%€7.97€5.47n/a2
Oct ’25€1.73
€6.56
+279.3%
17.6%€7.72€5.41n/a2
Sep ’25€1.95
€6.41
+228.6%
15.7%€7.41€5.40n/a2
Aug ’25€2.02
€6.39
+216.2%
16.2%€7.42€5.36n/a2
Jul ’25€2.12
€6.39
+201.3%
16.2%€7.42€5.36n/a2
May ’25€2.48
€5.75
+131.9%
26.6%€7.28€4.22n/a2
Apr ’25€2.75
€5.46
+98.7%
23.8%€7.26€4.22n/a3
Mar ’25€2.29
€5.47
+139.3%
23.9%€7.28€4.23n/a3
Feb ’25€2.27
€6.62
+192.4%
45.0%€10.81€4.19n/a3
Jan ’25€2.10
€6.58
+213.5%
44.9%€10.74€4.16n/a3
Dec ’24€1.72
€6.55
+280.2%
45.0%€10.71€4.18n/a3
Nov ’24€1.71
€6.76
+294.9%
40.6%€10.64€4.63€1.793
Oct ’24€2.25
€6.75
+200.8%
42.6%€10.81€4.54€1.733
Sep ’24€2.28
€6.75
+196.1%
42.6%€10.81€4.54€1.953
Aug ’24€2.57
€6.88
+167.7%
41.3%€10.90€4.80€2.023
Jul ’24€2.51
€6.88
+174.1%
41.3%€10.90€4.80€2.123
Jun ’24€2.52
€6.79
+169.9%
40.3%€10.66€4.78€2.703
May ’24€2.31
€6.79
+194.5%
40.3%€10.66€4.78€2.483
Apr ’24€2.52
€7.20
+185.7%
33.2%€10.57€5.34€2.753
Mar ’24€2.54
€6.80
+167.8%
39.4%€10.58€4.69€2.293
Feb ’24€2.86
€6.80
+137.8%
39.4%€10.58€4.69€2.273
Jan ’24€2.88
€6.84
+137.5%
38.3%€10.53€4.77€2.103
Dec ’23€3.24
€7.57
+133.6%
31.1%€10.82€5.36€1.723
Nov ’23€2.68
€7.76
+189.4%
26.9%€10.62€5.71€1.713

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

7D

0.6%

1Y

4.7%

Fortrea Holdings

US$1.8b

A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.

K67

US$18.40

7D

-1.6%

1Y

-38.3%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.29

7D

-1.8%

1Y

0.2%